跳至主要内容
临床试验/NCT03667365
NCT03667365终止不适用

Randomized Study for the Optimal Treatment of Symptomatic Patients With Low Gradient Severe Aortic Valve Stenosis and Preserved Left Ventricular Ejection Fraction

Rennes University Hospital18 个研究点 分布在 2 个国家目标入组 52 人开始时间: 2019年3月19日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
终止
发起方
入组人数
52
试验地点
18
主要终点
time from randomization to first occurrence of any of the components of the composite outcome (adjudicated): all-cause mortality or cardiovascular related hospitalization

研究概览

简要总结

According to current European Recommendations on valvular heart disease (VHD), "classical" severe aortic stenosis (AS) is defined by an aortic valve area (AVA) ≤1 cm2 and indexed AVA ≤0.6 cm2/m2, a mean aortic pressure gradient (MAG) >40 mmHg, and a maximal aortic velocity >4 m/sec.

Aortic valve replacement (AVR) is recommended (class I indication) in patients with "classical" severe AS who have any symptoms related to aortic valve disease.

In 2007, Hachicha et al. described a particular pattern of severe AS, characterized by an AVA ≤0.6 cm2/m2, low mean pressure aortic gradient (MAG <40 mmHg), despite the presence of a preserved left ventricular ejection fraction (LVEF ≥50%). This pattern of AS is encountered in nearly 15-25 % of patients who have severe AS. Typically, these patients are elderly subjects, with several comorbidities, a small left ventricular (LV) cavity with pronounced LV concentric remodeling and a restrictive physiology, leading to a decrease in LV stroke volume despite a preserved LVEF. The diagnosis and management of patients with low gradient severe AS and preserved LVEF are often challenging because:

  1. the presence of a "true" severe aortic stenosis should be carefully confirmed by a multi-modality imaging approach;
  2. the best therapeutic management (AVR versus conservative strategy) of symptomatic patients with low gradient severe AS and preserved LVEF is not clearly established.

In very recently updated European guidelines on the management of VHD, symptomatic patients with low gradient and low flow severe AS and preserved LVEF have only a class IIa-level C indication for AVR. No specific indications are given for the management of symptomatic patients with low gradient and normal flow severe AS. This lack of indications is clearly attributed to a gap in knowledge which requires further investigations to be filled up.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Age >18 years
  • •Symptomatic and severe AS defined by an effective AVA ≤1 cm² and indexed AVA ≤0.6 cm2/m2
  • •MAG <40 mm Hg (measure confirmed by the multi-window continuous-wave Doppler interrogation and use of Pedoff probe)
  • •Confirmation of the presence of severe AS at DSE and MDCT aortic calcium score
  • •Feasibility of AVR by surgery or TAVR according to the "heart team"
  • •Signature of an informed consent

排除标准

  • •Uncontrolled atrial of ventricular arrhythmias
  • •Patient having a life expectancy <1 year, independently from their aortic pathology
  • •Coronary artery disease necessitating a percutaneous or surgical revascularisation
  • •Presence of a concomitant valve disease needing surgical treatment
  • •Patient who are included in another research protocol
  • •Protected person (adults legally protected (under judicial protection, guardianship or supervision), person deprived of their liberty, pregnant woman, lactating woman and minor)

研究组 & 干预措施

aortic valve replacement

Experimental

干预措施: aortic valve replacement (Procedure)

strict clinical surveillance

Active Comparator

干预措施: strict clinical surveillance (Other)

结局指标

主要结局

time from randomization to first occurrence of any of the components of the composite outcome (adjudicated): all-cause mortality or cardiovascular related hospitalization

时间窗: during 2 years follow-up

次要结局

  • rate of cardiovascular mortality(2 years)
  • rate of cerebrovascular events(2 years)
  • rate of all-cause mortality(2 years)
  • rate of cardiovascular related hospitalization(2 years)
  • NT-proBNP plasma levels(6, 12, 18 and 24 months)
  • quality of life score(6, 12, 18 and 24 months)
  • walking distance(6, 12, 18 and 24 months)

研究者

发起方
Rennes University Hospital
申办方类型
Other
责任方
Sponsor

研究点 (18)

Loading locations...

相似试验